Granulocyte-Macrophage Colony-Stimulating Factor
Sponsors
University of Chicago, Zhejiang Cancer Hospital, GlaxoSmithKline, Mayo Clinic, Tufts Medical Center
Conditions
Advanced Lung Non-Small Cell CarcinomaArthritis, RheumatoidBreast Ductal Carcinoma In SituCervical CancerGlioblastoma MultiformeMelanoma (Skin)Neuroblastoma RecurrentNon-Small Cell Carcinoma of Lung, TNM Stage 4
Phase 1
Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
CompletedNCT03306589
Start: 2017-08-11End: 2018-06-20Updated: 2019-08-08
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
RecruitingNCT04144023
Start: 2019-06-27End: 2027-12-31Target: 43Updated: 2026-03-05
Phase 2
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
CompletedNCT00004141
Start: 1998-08-31End: 2006-04-30Updated: 2013-09-05
Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
NCT02663440
Start: 2016-01-31Target: 41Updated: 2016-01-26
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
TerminatedNCT04856176
Start: 2022-01-03End: 2024-12-06Updated: 2025-01-01
Quadruple Immunotherapy for Neuroblastoma
RecruitingNCT05754684
Start: 2022-01-01End: 2025-12-31Target: 29Updated: 2025-09-15
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
RecruitingNCT05817214
Start: 2023-02-16End: 2027-02-28Target: 35Updated: 2024-04-19